Translate
Subscribe to Blog via Email
Ronny Allan
When I was being told I had an advanced and incurable cancer, I did what most people seem to do in movies ….. I asked “how long do I have“. The Oncologist said ” … perhaps just months“. That must have been quite a shock because for a few moments after that, I heard nothing – my brain was clearly still trying to process those words – I wasn’t even feeling unwell! The really important bit I missed was him go on to say “…but with the right treatment, you should be able to live for a lot longer”. Fortunately, my wife Chris heard it all and I was refocused. “OK Doc – let’s go” I said. Always take someone with you to take notes at important meetings with Oncologists!
However, I now realise he was guessing because no-one really knows how long a person with Neuroendocrine Cancer will live. Sure, they can tell you averages from known data but that data is out of date as soon as it’s published. I did have a peek at some data I found shortly after that conversation and spotted a 5 year survival rate of 38% – that was also a shock. In those days I was naïve though, I hadn’t really appreciated the complexity behind survival data (and therefore how to read and interpret it) and more obviously, I hadn’t realised the data I was looking at, was really really old, predated most of the new treatments around today; and that it might be skewed by mixing low and high grade data. Nor did I appreciate the sheer number of factors involved in Neuroendocrine Cancer prognostics which can make ‘fortune telling’ a more complex task than many other cancers, e.g. grade, stage, primary location, functional/non-functional, age, cancer side effects, the patient’s pre-existing conditions, location, access to a specialist, healthcare system. Although I accept some of these factors are the same across the cancer board. Stage and Grade are interesting because with very aggressive cancers, stage can often be a real differentiator. With Neuroendocrine Cancer it can often be the opposite – grade can make a huge difference between a good and not so good prognostic outlook, i.e. with well differentiated low grade Neuroendocrine Tumours, Stage 4 is not the ‘red flag’ it is for more aggressive cancers.
For those looking online for NETs prognostic data, I offer the following advice:
- Be careful surfing the internet, some sites have NETs prognostic data from the ark.
- Even if you find the very latest data, interpretation is difficult due to the heterogeneity of NETs, different stages and grades, comorbidities, age, access to a specialist, access to latest therapy, and no doubt many other factors. Please also note that even the ‘very latest’ data is probably a few years old.
- It’s a difficult question even for a specialist.
- I’ve lost count of the number of people who have told their story about being given a period of time from their specialist (including use of the word ‘terminal’) and they are still here a significant period after, in some cases 10 x what their specialist said.
- Personally, I’ve given up paying any attention to prognostic data. Check out the comments from NET patients on this Facebook post – click here – this is the only thing I now pay attention to.
- Here’s a much better question people should be asking ……“How do I live with NETs?”
However, if you do take the plunge and pose this question to your Oncologist or Specialist, you may get a really woolly answer. I wouldn’t be too disappointed, they’re not fortune tellers – they simply don’t know and it can often be an expectation they don’t want to manage on your behalf.
The motiavtion (and the inspriation) to write this artilce comes from a tweet by well known NET Specialist Dr Pamela Kunz who indicated she doesn’t have a crystal ball (the exact words are on the tweet snapshot photo below). The story is proof that patients really want to help doctors do their job. The purchase of a crystal ball as a gift for Dr Kunz is quite amusing, inspiring and should lift the sprits of anyone reading.

I’m so pleased that Dr Kunz shared this story, it’s a great message for both doctors and patients to hear. I’m also grateful to Dr Kunz for allowing me to use her photo in the article.

Edit:
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Personal Facebook. Like this page please.
Blog Facebook. Like this page please.
Awareness Facebook Like this page please.
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient

Neuroendocrine Cancer: Question, Clarify, Confirm
One of the many observations I make in my private Neuroendocrine Cancer Facebook group is the misunderstandings caused by the use of non-standard terminology combined

Clinical Trial – Lutathera NETTER-2 Important Update
UPDATE – Sep 25th, 2023 – Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors

Lanreotide: Ipsen injection devices vs generic injection devices
Whenever I get a chance to talk to a pharma involved in somatostatin analogue injection devices, I tell them one very important thing …… “To

Cancer doesn’t take holidays (but I do)
Glen Etive Scotland in 2018 After diagnosis in July 2010, with the exception of a planned holiday to Turkey prior to my ‘big surgery’, holidays

Update from Ronny Allan: No evidence of progressive disease at any site
Update August 2023. Latest CT surveillance scan reports “No evidence of progressive disease at any site”. Very pleased! With incurable but treatable cancers such as

Exercise is Medicine
Exercise is medicine. Clearly I need to be careful with that statement given my aversion for cancer myths. However, those who know me will totally

Jimmy Buffett 1946-2023 – Neuroendocrine Carcinoma (Merkel Cell Carcinoma)
US singer-songwriter Jimmy Buffett, best known for his 1970’s hit Margaritaville, has died aged 76. “Jimmy passed away peacefully on the night of September 1

Passive patient or active advocate?
I’ve been researching Neuroendocrine Cancer for some time now. Why do I do this? Whilst I have a great medical team, I’d also like to

Childhood Cancer Awareness Month – Neuroendocrine Cancer (featuring Elizabeth)
September is Childhood Cancer Awareness Month! The newspapers and social media will no doubt be featuring many childhood cancer articles. You may not see one
new options all the time….indeed incurable or terminal now does not mean untreatable and more and more treatments extend survival. Have you been able to access Lutathera anyone?
Probably a better question for my group but I can tell you many many many people are, thus why prognostics are improving